Anatomic Pathology Track & Trace Solution Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Anatomic Pathology Track & Trace Solution Market is projected to expand from USD 673.93 Million in 2025 to USD 1.03 billion by 2031, registering a CAGR of 7.48%. These solutions comprise integrated hardware and software architectures designed to monitor biological specimens throughout the entire laboratory workflow, guaranteeing precise identification and maintaining a strict chain of custody. The market's growth is primarily driven by the rising global incidence of chronic diseases that demand tissue diagnostics and the imperative need to eliminate pre-analytical errors that endanger patient safety. Additionally, rigorous regulatory requirements for laboratory accreditation are compelling facilities to adopt these automated identification technologies to lower liability risks and enhance operational efficiency.

Despite these positive drivers, the market faces obstacles due to the substantial capital required for implementation and the difficulties involved in integrating these systems with existing laboratory information infrastructures. This barrier is further exacerbated by the increasing strain on diagnostic resources, which demands higher efficiency while simultaneously tightening financial budgets. According to the American Cancer Society, approximately 2,001,140 new cancer cases were projected to occur in the United States in 2024. This escalating volume of diagnostic demand highlights the urgent necessity for robust tracking capabilities, even as economic challenges complicate their acquisition.

Market Drivers

The rising global burden of cancer and chronic diseases serves as a major catalyst for the implementation of anatomic pathology track and trace solutions, creating a fundamental need for greater throughput and precision in tissue diagnostics. As oncological conditions become more prevalent, laboratories are under immense pressure to process growing volumes of biopsy specimens rapidly without sacrificing accuracy. This surge in diagnostic demand necessitates automated tracking systems to oversee complex workflows and guarantee specimen integrity from the point of collection to archiving. Highlighting this need for scalable infrastructure, the American Cancer Society's 'Cancer Facts & Figures 2025' report, released in January 2025, estimates that 2,041,910 new cancer cases will be diagnosed in the United States alone.

Simultaneously, the imperative to reduce diagnostic errors and misidentification acts as a powerful driver, pushing laboratories to adopt robust chain-of-custody technologies to ensure patient safety. Because manual labeling and handling are increasingly seen as risky and untenable, there is a distinct shift toward barcode and RFID-enabled tracking to mitigate liability and meet strict quality standards. This emphasis on safety is underscored by industry monitors; in March 2025, ECRI's 'Top 10 Patient Safety Concerns 2025' report listed diagnostic errors related to cancers and major vascular events as the seventh most critical challenge. Furthermore, regulatory compliance strengthens this trend, illustrated by the College of American Pathologists' March 2025 report, which noted that a record 657 laboratories achieved initial accreditation in 2024, signaling a deepening commitment to standardized, error-free operations.

Market Challenges

The significant capital investment needed to deploy anatomic pathology track and trace solutions represents a major hurdle to market growth. Laboratories must contend with high upfront costs for essential hardware and software, a challenge that is further complicated by the expense of interfacing these modern tools with legacy laboratory information systems. This financial strain is particularly acute for smaller, independent facilities that operate with limited budgets and lack the resources to easily absorb the costs associated with infrastructure upgrades or staff retraining for complex integrated networks.

These economic difficulties are intensified by external financial constraints that restrict the funds available for technological enhancements. When laboratories face diminished revenue streams, they are often compelled to prioritize immediate operational costs over capital equipment investments. According to the College of American Pathologists, the final Medicare Physician Fee Schedule in 2024 led to an overall payment reduction of approximately 2 percent for pathology services. This contraction in reimbursement directly hampers the ability of pathology groups to budget for automated tracking systems, delaying their adoption despite the evident operational advantages.

Market Trends

The convergence of track and trace systems with digital pathology workflows is rapidly becoming a transformative trend, evolving the market from physical tracking to comprehensive diagnostic data management. This integration addresses the increasing need to link physical specimens with their digital counterparts, such as whole slide images (WSI), ensuring the chain of custody persists into the virtual diagnostic realm. As remote sign-out and telepathology gain traction, maintaining synchronized identification between glass slides and their digital twins is essential for operational continuity. According to Labcorp's '2024 Lab Leader Report' from February 2024, approximately 33% of laboratory decision-makers have initiated or planned digital pathology workflows, driving a parallel demand for tracking solutions that bridge the physical-digital divide.

Concurrently, seamless interoperability with Laboratory Information Systems (LIS) and Electronic Health Records (EHR) has become a primary market requirement, necessitating deep, bi-directional data integration rather than simple connectivity. Laboratories are moving away from standalone tracking solutions that generate data silos, preferring systems that automatically populate accession data and update case status in real-time across the enterprise IT landscape. This trend is motivated by the need to eliminate redundant data entry and ensure specimen location data is instantly available to clinicians. The urgency of this issue is highlighted by the '2024 State of the Industry Survey' from Medical Laboratory Observer in April 2024, where 51% of laboratory professionals cited interoperability and data integration challenges as significant hurdles, thereby influencing the market's preference for open-architecture tracking platforms.

Key Players Profiled in the Anatomic Pathology Track & Trace Solution Market

• Leica Biosystems Nussloch GmbH
• Thermo Fisher Scientific Inc.
• Zebra Technologies Corp.
• Agilent Technologies Inc.
• CompuGroup Medical
• LigoLab Information Systems
• General Data Healthcare Inc.
• Psyche Systems Corporation
• Siemens Healthineers AG
• Indica Labs, LLC

Report Scope

In this report, the Global Anatomic Pathology Track & Trace Solution Market has been segmented into the following categories:

Anatomic Pathology Track & Trace Solution Market, by Application:

• Slides Tracking
• Specimen Tracking
• Tissue Cassettes & Blocks Tracking

Anatomic Pathology Track & Trace Solution Market, by End User:

• Hospital Laboratories
• Independent & Reference Laboratories
• Others

Anatomic Pathology Track & Trace Solution Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anatomic Pathology Track & Trace Solution Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.